KCT0000328
Recruiting
未知
A multicenter, randomized trial to assess efficacy of home-based and group cognitive intervention programs in amnestic mild cognitive impairment
ConditionsMental and behavioral disorders
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Mental and behavioral disorders
- Sponsor
- Inha University Hospital
- Enrollment
- 270
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.50 to 85 years of age
- •2\.memory complaint corroborated by a participant and an informant
- •3\.delayed recall score on the Seoul Verbal Learning Test (SVLT) at or below 1\.5 standard deviations from the mean of the age and education\-normative values among the Korean population
- •4\. Global CDR score is 0\.5, Memory CDR score is 0\.5 or 1\.
- •5\. at or above 1\.5 standard deviations from the mean of normative data of the respective age\- and education\-matched population on the Korean Mini\-Mental State Examination
- •6\. normal functional activities
- •7\. Not diagnosed with dementia
- •8\. Modified Hachinski Ischemic Score (HIS): 0\-4
- •9\. brain magnetic resonance imaging or CT showing no clinical evidence of other diseases (i.e., normal pressure hydrocephalus, brain tumor, cerebrovascular disease) capable of producing cognitive impairment.
- •10\. Subjects are also required to have a reliable caregiver who meet the patient at least once a week and is sufficiently familiar with the patient to provide the investigator with accurate information.
Exclusion Criteria
- •1\. any patient who were involved in other clinical trials or treated with experimental drug within 4 weeks
- •2\. any patients with any severe or unstable medical disease that may prevent the patient from completing all study requirements (i.e., unstable or severe asthma or cardiovascular disease, active gastric ulcer, severe hepatic or renal disease)
- •3\. any patients with clinically significant laboratory abnormalities such as an abnormal thyroid function test, abnormal low level of vitamin B12 or folate, or positive venereal disease research laboratory test
- •4\. any patients with any primary neurodegenerative disorder or psychiatric disorder other than AD (i.e., Parkinson's disease, schizophrenia, or major depressive disorder)
- •5\. any patiens with any history of drug or alcohol addiction during the past 10 years
- •6\. any hearing or visual impairment that can disturb the efficient evaluation of the patient
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A randomized multicenter study evaluating efficacy, safety, tolerability and pharmacokinetics of AEB071 combined with tacrolimus or mycophenolate mofetil (MMF) vs. a tacrolimus-based control regimen in de novo liver transplant recipients.EUCTR2007-001776-36-GBovartis Pharma Services AG
Active, not recruiting
Not Applicable
A randomized, multicenter study, evaluating efficacy, safety, tolerability and pharmacokinetics of AEB071 combined with tacrolimus or mycophenolate mofetil (MMF) vs a tacrolimus-based control regimen in de novo liver transplant recipients - NDde novo liver transplant recipientsMedDRA version: 9.1Level: LLTClassification code 10024714Term: Liver transplantEUCTR2007-001776-36-ITOVARTIS FARMA320
Active, not recruiting
Not Applicable
Enterosgel® in the treatment of atopic dermatitis in adultsAtopic dermatitisSkin and Connective Tissue DiseasesISRCTN12307286Enteromed Ltd44
Not yet recruiting
Not Applicable
A multicenter clinical study to test the efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolism.clinical amnitotic fluid embolismJPRN-UMIN000012273Department of Obstetrics and Gynecology, Mie university hospital.5
Completed
Not Applicable
A multicentre, randomised clinical trial to evaluate the efficacy of oral ciprofloxacin, oral tamsulosin, and the combination of oral ciprofloxacin and oral tamsulosin for the treatment of Chronic Prostatitis/Chronic Pelvic Pain SyndromeISRCTN85291415ational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIDDK, NIH) (USA)184